

**FOR IMMEDIATE RELEASE****Burrill & Company Announces Initiation of Burrill Capital Fund IV, L.P. Operations**

San Francisco, CA—December 19, 2011— Burrill & Company today announced that effective December 1, 2011, its Burrill Capital Fund IV, L.P. commenced operations with aggregate capital commitments of \$313 million.

The fund will invest globally in the life sciences, including early- to late-stage investments in therapeutics, diagnostics, medical devices, healthcare delivery, wellness, and digital health.

“We are pleased to have surpassed our initial goal of \$300 million in capital commitments for the first close,” says G. Steven Burrill, CEO of Burrill & Company, a global life sciences financial services firm. “We look forward to achieving our final goal of \$500 million in capital commitments by June 2012.”

**About Burrill & Company**

Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than \$1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking, and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: [www.burrillandco.com](http://www.burrillandco.com).

**Contact:**

Daniel Levine  
Managing Director  
Burrill & Company  
[dlevine@b-c.com](mailto:dlevine@b-c.com)  
415-591-5449